GGrantIndex
← Leaderboards

Leo Luznik

Johns Hopkins University

$5,973,496
Attributed
$6,805,017
Total exposure
7
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $731.2K · FY200524
$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24

Funding mix

By agency

NIH$6,805,017 · 7

By mechanism

R01$3,114,009 · 2
P01$3,007,053 · 4
K08$683,955 · 1

Top collaborators

Most similar at Johns Hopkins University

Same institution · by research overlap

Others in their field

Top investigators on “Tumor

Research focus

TumorT-LymphocyteAllogenicBloodResponseIn VivoBone Marrow TransplantationAntigensImmuneMolecularBaseClinical TrialsImmunityTherapeutic EffectivenessAutologousTumor ImmunityHuman DiseaseSignaling MoleculeLigandsSourceRelapseCytokineFlow CytometryInsight

Grant awards (27)

Immune Monitoring Core$157,383
P01 · FY2024 · CA · contact PI
Marrow-Infiltrating Lymphocytes$20,652
P01 · FY2024 · CA · contact PI
Immune Monitoring Core$257,570
P01 · FY2023 · CA · contact PI
Marrow-Infiltrating Lymphocytes$177,064
P01 · FY2023 · CA · contact PI
Immune Monitoring Core$354,738
P01 · FY2022 · CA · contact PI
Marrow-Infiltrating Lymphocytes$243,858
P01 · FY2022 · CA · contact PI
Immune Monitoring Core$354,738
P01 · FY2021 · CA · contact PI
Marrow-Infiltrating Lymphocytes$243,858
P01 · FY2021 · CA · contact PI
Immune Monitoring Core$354,738
P01 · FY2020 · CA · contact PI
Marrow-Infiltrating Lymphocytes$243,858
P01 · FY2020 · CA · contact PI
Immune Monitoring Core$354,738
P01 · FY2019 · CA · contact PI
Marrow-Infiltrating Lymphocytes$243,858
P01 · FY2019 · CA · contact PI
MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE$414,751
R01 · FY2015 · HL · contact PI
MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE$412,570
R01 · FY2014 · HL · contact PI
MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE$399,948
R01 · FY2013 · HL · contact PI
MECHANISMS OF GVHD PREVENTION WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE$435,773
R01 · FY2012 · HL · contact PI
Augmenting Antitumor Immunity after Allografting$295,461
R01 · FY2012 · CA · contact PI
Augmenting Antitumor Immunity after Allografting$281,662
R01 · FY2011 · CA · contact PI
Augmenting Antitumor Immunity after Allografting$290,836
R01 · FY2010 · CA · contact PI
Augmenting Antitumor Immunity after Allografting$291,285
R01 · FY2009 · CA · contact PI
Augmenting Antitumor Immunity after Allografting$291,723
R01 · FY2008 · CA · contact PI
TUMOR VACCINES AFTER NON MYELOABLATIVE ALLOGRAFTING$56,996
K08 · FY2006 · CA · contact PI
TUMOR VACCINES AFTER NON MYELOABLATIVE ALLOGRAFTING$136,791
K08 · FY2005 · CA
TUMOR VACCINES AFTER NON MYELOABLATIVE ALLOGRAFTING$136,791
K08 · FY2004 · CA
TUMOR VACCINES AFTER NON MYELOABLATIVE ALLOGRAFTING$136,791
K08 · FY2003 · CA
TUMOR VACCINES AFTER NON MYELOABLATIVE ALLOGRAFTING$79,795
K08 · FY2002 · CA
TUMOR VACCINES AFTER NON MYELOABLATIVE ALLOGRAFTING$136,791
K08 · FY2001 · CA